Neuberger Berman Group LLC Cassava Sciences Inc Transaction History

Neuberger Berman Group LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Nov 14, 2024	BUY	$12.64 - $30.11 $752,433 - $1.79 Million	59,528 New	59,528 $1.34 Million
Q4 2023 Feb 09, 2024	SELL	$12.64 - $30.11 $58,763 - $139,981	-4,649 Reduced 7.24%	59,528 $1.34 Million
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $265,391 - $403,828	15,949 Added 33.07%	64,177 $1.07 Million
Q2 2023 Aug 11, 2023	SELL	$21.59 - $27.88 $928 - $1,198	-43 Reduced 0.09%	48,228 $1.18 Million
Q1 2023 May 12, 2023	BUY	$23.46 - $36.44 $3,612 - $5,611	154 Added 0.32%	48,271 $1.16 Million
Q4 2022 Feb 13, 2023	BUY	$27.82 - $44.16 $1,251 - $1,987	45 Added 0.09%	48,117 $1.42 Million
Q3 2022 Nov 15, 2022	BUY	$16.33 - $51.06 $1,175 - $3,676	72 Added 0.15%	48,072 $2.01 Million
Q2 2022 Aug 15, 2022	BUY	$17.22 - $38.47 $86,100 - $192,350	5,000 Added 11.63%	48,000 $1.35 Million
Q1 2022 May 13, 2022	BUY	$32.6 - $53.05 $163,000 - $265,250	5,000 Added 13.16%	43,000 $1.6 Million
Q4 2021 Feb 11, 2022	BUY	$36.77 - $90.91 $110,310 - $272,730	3,000 Added 8.57%	38,000 $1.66 Million
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $543,270 - $1.76 Million	13,000 Added 59.09%	35,000 $2.17 Million
Q2 2021 Aug 13, 2021	BUY	$32.15 - $89.72 $482,250 - $1.35 Million	15,000 Added 214.29%	22,000 $1.88 Million
Q1 2021 May 13, 2021	BUY	$7.09 - $87.95 $49,630 - $615,650	7,000 New	7,000 $315,000

196

13.8M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $101M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.